Stocklytics Platform
Asset logo for symbol SNDX
Syndax Pharmaceuticals
SNDX52
$14.92arrow_drop_down1.06%-$0.16
Asset logo for symbol SNDX
SNDX52

$14.92

arrow_drop_down1.06%

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Syndax Pharmaceuticals (SNDX) Stocklytics Forecast

Syndax Pharmaceuticals Inc (SNDX) is a biopharmaceutical company that focuses on developing innovative therapies to target cancer. The company is known for its novel approach to treatment, which involves targeting the immune system to fight cancer cells. SNDX has experienced significant growth in recent years, with its stock price reaching impressive highs. Many investors are optimistic about the future of SNDX and have made various predictions and forecasts regarding its stock price for the coming years.
According to market analysts, SNDX has the potential for significant growth in the near future. Some predict that the stock price could double or even triple in the next few years. These predictions are based on several factors, including the company's strong pipeline of potential drugs and its positive clinical trial results. Furthermore, SNDX has formed strategic partnerships with other pharmaceutical companies, which provides additional opportunities for growth and expansion.
add Syndax Pharmaceuticals to watchlist

Keep an eye on Syndax Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Syndax Pharmaceuticals (SNDX) stock?

Analysts have set a target price of $37.3 for Syndax Pharmaceuticals (SNDX), based on forecasts from 23 analysts. The predicted price range extends from a high of $45 to a low of $23. This represents a potential increase of up to 201.61% and a decrease of 54.16% from the current price of $14.92. These forecasts are as of 2023 Jun 26.
help

What are the analyst ratings for Syndax Pharmaceuticals (SNDX) stock?

The analyst ratings for Syndax Pharmaceuticals (SNDX) are distributed as follows: 14 analysts recommend buying, 1 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 15 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Syndax Pharmaceuticals .
help

What is the AI price prediction for Syndax Pharmaceuticals (SNDX) stock?

At present, there is no AI or machine-learning-based price prediction available for Syndax Pharmaceuticals (SNDX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level